Literature DB >> 33673949

Novelties in Therapy of Chronic Heart Failure.

Sara Doimo1, Daniela Pavan2.   

Abstract

In recent decades, considerable advances have been made in the treatment of heart failure. The main target of heart failure therapy is the inhibition of the sympathetic nervous system and renin-angiotensin-aldosterone system. The angiotensin receptor blockers represent a breakthrough in the treatment of heart failure with a demonstrated effect on reduction of cardiovascular events. However, new perspectives derive from latest drugs developed for diabetes, iron deficiency, and hyperkalemia. New frontiers are also opened to the development of neurohormonal therapies, antagonists of inflammatory mediators, inotropic agents, and cell-based treatments.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic heart failure; Comorbidities; Neurohormonal antagonists; New therapies; Preserved ejection fraction; Reduced ejection fraction

Year:  2021        PMID: 33673949     DOI: 10.1016/j.hfc.2021.01.006

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  2 in total

1.  Qishen Yiqi dropping pills improve isoproterenol-induced cardiomyocyte hypertrophy by regulating X-inactive specific transcript (XIST) expression in rats.

Authors:  Ying Luo; Jiaxian Chen; Yuewu Chen; Yangshen Su; Xiaoyan Wu; Wanling Zheng; Xianxia Liu; Lei Chen
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial.

Authors:  Shervin G Hoseini; Kiyan Heshmat-Ghahdarijani; Saeid Khosrawi; Mohammad Garakyaraghi; Davood Shafie; Marjan Mansourian; Hamidreza Roohafza; Elham Azizi; Masoumeh Sadeghi
Journal:  Clin Cardiol       Date:  2022-02-16       Impact factor: 3.287

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.